Valuation recommendations. We expect the company's earnings per share for 12-14 years (after dilution) to be 0.73/0.93/1.11 yuan, respectively. Currently, the industry is in a stage of rapid development. We believe that the reasonable price range for the company is 18.25-20.44 yuan, and the corresponding valuation ranges for 2012-2014 are 25.00-28.00 times, 19.62-21.98 times, and 16.44-18.41 times.
【中航证券】双成药业:技术领先的多肽类药物生产企业
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.